234 related articles for article (PubMed ID: 8053405)
1. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.
Green JR; Müller K; Jaeggi KA
J Bone Miner Res; 1994 May; 9(5):745-51. PubMed ID: 8053405
[TBL] [Abstract][Full Text] [Related]
2. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
van der Pluijm G; Binderup L; Bramm E; van der Wee-Pals L; De Groot H; Binderup E; Löwik C; Papapoulos S
J Bone Miner Res; 1992 Aug; 7(8):981-6. PubMed ID: 1442212
[TBL] [Abstract][Full Text] [Related]
3. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
[TBL] [Abstract][Full Text] [Related]
4. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density.
Ammann P; Rizzoli R; Caverzasio J; Shigematsu T; Slosman D; Bonjour JP
J Bone Miner Res; 1993 Dec; 8(12):1491-8. PubMed ID: 8304051
[TBL] [Abstract][Full Text] [Related]
5. Human cystatin C, a cysteine proteinase inhibitor, inhibits bone resorption in vitro stimulated by parathyroid hormone and parathyroid hormone-related peptide of malignancy.
Lerner UH; Grubb A
J Bone Miner Res; 1992 Apr; 7(4):433-40. PubMed ID: 1319105
[TBL] [Abstract][Full Text] [Related]
6. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone.
Liu CC; Kalu DN; Salerno E; Echon R; Hollis BW; Ray M
J Bone Miner Res; 1991 Oct; 6(10):1071-80. PubMed ID: 1796755
[TBL] [Abstract][Full Text] [Related]
7. [Effects of bisphosphonates on vitamin A-induced bone resorption in thyroparathyroidectomized rat].
Gen M
Nihon Seikeigeka Gakkai Zasshi; 1995 Nov; 69(11):1193-207. PubMed ID: 8568374
[TBL] [Abstract][Full Text] [Related]
8. The cyclic-AMP antagonist adenosine-3',5'-cyclic monophosphosphorothioate, RP-isomer inhibits parathyroid hormone induced bone resorption, in vitro.
Ljunggren O; Ljunghall S
Biochem Biophys Res Commun; 1993 Jun; 193(3):821-6. PubMed ID: 8391806
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology of zoledronic acid.
Green JR
Semin Oncol; 2002 Dec; 29(6 Suppl 21):3-11. PubMed ID: 12584689
[TBL] [Abstract][Full Text] [Related]
10. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
[TBL] [Abstract][Full Text] [Related]
11. Effect of a single injection of two new bisphosphonates on the hypercalcemia and hypercalciuria induced by Walker carcinosarcoma 256/B in thyroparathyroidectomized rats.
Kozak S; Rizzoli R; Trechsel U; Fleisch H
Cancer Res; 1987 Dec; 47(23):6193-7. PubMed ID: 3677071
[TBL] [Abstract][Full Text] [Related]
12. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
13. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH.
Ueno Y; Shinki T; Nagai Y; Murayama H; Fujii K; Suda T
J Cell Biochem; 2003 Oct; 90(2):267-77. PubMed ID: 14505343
[TBL] [Abstract][Full Text] [Related]
14. [A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].
Nakayama Y; Okuno S; Miki T; Nishizawa Y; Morii H
Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1294-9. PubMed ID: 1291340
[TBL] [Abstract][Full Text] [Related]
15. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone.
Hock JM; Gera I
J Bone Miner Res; 1992 Jan; 7(1):65-72. PubMed ID: 1532281
[TBL] [Abstract][Full Text] [Related]
16. Menatetrenone inhibits bone resorption partly through inhibition of PGE2 synthesis in vitro.
Hara K; Akiyama Y; Tajima T; Shiraki M
J Bone Miner Res; 1993 May; 8(5):535-42. PubMed ID: 8511981
[TBL] [Abstract][Full Text] [Related]
17. Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate.
Weissglas M; Löwik C; Schamhart D; Theuns H; Kurth KH; Papapoulos S
BJU Int; 2007 Jun; 99(6):1530-3. PubMed ID: 17428243
[TBL] [Abstract][Full Text] [Related]
18. Effects of two novel bisphosphonates on bone cells in vitro.
Evans CE; Braidman IP
Bone Miner; 1994 Aug; 26(2):95-107. PubMed ID: 7994190
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo.
Uy HL; Mundy GR; Boyce BF; Story BM; Dunstan CR; Yin JJ; Roodman GD; Guise TA
Cancer Res; 1997 Aug; 57(15):3194-9. PubMed ID: 9242449
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]